FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Stem Cell Res Ther / Inflammatory licensed equine MSCs are chondroprotective and ...
Stem cell research & therapy2018; 9(1); 82; doi: 10.1186/s13287-018-0840-2

Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment.

Abstract: Inflammatory licensed mesenchymal stem cells (MSCs) have the ability to promote functional tissue repair. This study specifically sought to understand how the recipient tissue environment reciprocally affects MSC function. Inflammatory polarized macrophages, modeling an injured tissue environment, were exposed to licensed MSCs, and the resultant effects of MSC immunomodulation and functionality of the MSC secretome on chondrocyte homeostasis were studied. Inflammatory licensed MSCs were generated through priming with either IFN-γ or polyinosinic:polycytidylic acid (poly I:C). Macrophages were polarized to an inflammatory phenotype using IFN-γ. Licensed MSCs were co-cultured with inflammatory macrophages and immunomodulation of MSCs was assessed in a T-cell proliferation assay. MSC gene expression was analyzed for changes in immunogenicity (MHC-I, MHC-II), immunomodulation (IDO, PTGS2, NOS2, TGF-β1), cytokine (IL-6, IL-8), and chemokine (CCL2, CXCL10) expression. Macrophages were assessed for changes in cytokine (IL-6, IL-10, TNF-α, IFN-γ) and chemokine (CCL2, CXCL10) expression. Conditioned medium representing the secretome from IFN-γ or poly I:C-primed MSCs was applied to IL-1β-stimulated chondrocytes, which were analyzed for catabolic (IL-6, TNF-α, CCL2, CXCL10, MMP-13, PTGS2) and matrix synthesis (ACAN, COL2A1) genes. IFN-γ-primed MSCs had a superior ability to suppress T-cell proliferation compared to naïve MSCs, and this ability was maintained following exposure to proinflammatory macrophages. In naïve and licensed MSCs exposed to inflammatory macrophages, MHC-I and MHC-II gene expression was upregulated. The secretome from licensed MSCs was chondroprotective and downregulated inflammatory gene expression in IL-1β-stimulated chondrocytes. In-vitro inflammatory licensing agents enhanced the immunomodulatory ability of MSCs exposed to inflammatory macrophages, and the resultant secretome was biologically active, protecting chondrocytes from catabolic stimulation. Use of licensing agents produced a more consistent immunomodulatory MSC population compared to exposure to inflammatory macrophages. The clinical implications of this study are that in-vitro licensing prior to therapeutic application could result in a more predictable immunomodulatory and reparative response to MSC therapy compared to in-vivo inflammatory licensing by the recipient environment.
Get Full Text
Publication Date: 2018-04-03 PubMed ID: 29615127PubMed Central: PMC5883371DOI: 10.1186/s13287-018-0840-2Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study explores the effects of using inflammatory licensed mesenchymal stem cells (MSCs) to promote tissue repair. The researchers found that these stem cells not only modulate immune responses but are also protective of cartilage cells, providing potential new avenues for MSC therapies.

Objective of Research

The primary goal of this research was to understand how the environmental conditions inside a recipient body affect the functioning of mesenchymal stem cells (MSCs) that have been modified through inflammatory licensing. The researchers also wanted to understand the impact of the MSC secretome – the substances secreted by these stem cells – on the stability of chondrocytes, or cartilage cells.

Methodology

  • The scientists generated inflammatory licensed MSCs by priming with interferon-gamma (IFN-γ) or polyinosinic:polycytidylic acid, also known as poly I:C.
  • They then polarized macrophages, a type of white blood cell, to an inflammatory phenotype using IFN-γ. These macrophages were designed to mimic an injured tissue environment.
  • The licensed MSCs were co-cultured with this inflammatory environment and their ability to modulate the immune response was assessed.
  • They analyzed gene expression in the MSCs to observe any changes relating to immunogenicity, immunomodulation, cytokine levels, and chemokine expression.
  • The scientists also studied the effects on macrophages, looking at changes in cytokine and chemokine expression there.
  • The medium from the IFN-γ or poly I:C-primed MSCs, representing their secretome, was applied to chondrocytes that had been stimulated by IL-1β. They then analyzed these chondrocytes for alterations in genes associated with catabolic action and matrix synthesis.

Findings of the Research

  • The study found that IFN-γ-primed MSCs were better equipped at suppressing T-cell proliferation compared to their unprimed counterparts. Their ability was preserved even after exposure to inflammatory macrophages.
  • MHC-I and MHC-II gene expression was upregulated in both licensed and unlicensed MSCs when exposed to inflammatory macrophages.
  • The secretome from licensed MSCs had a protective effect on chondrocytes and decreased inflammatory gene expression in chondrocytes triggered by IL-1β.
  • Furthermore, they found that inflammatory agents in vitro improved immunomodulation ability of MSCs exposed to inflammatory macrophages and the resulting secretome protected chondrocytes against catabolic stimulation.

Clinical Implications

The study found that in-vitro licensing prior to therapeutic application can result in a more consistent and predictable immune and reparative response to MSC therapy compared to in-vivo inflammatory licensing. This is a significant finding, as it could lead to the development of more effective MSC therapies for conditions that involve cartilage damage or degeneration, such as osteoarthritis or rheumatoid arthritis.

Cite This Article

APA
Cassano JM, Schnabel LV, Goodale MB, Fortier LA. (2018). Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment. Stem Cell Res Ther, 9(1), 82. https://doi.org/10.1186/s13287-018-0840-2

Publication

Stem cell research & therapy
ISSN: 1757-6512
NlmUniqueID: 101527581
Country: England
Language: English
Volume: 9
Issue: 1
Pages: 82
PII: 82

Researcher Affiliations

Cassano, Jennifer M
  • Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA.
Schnabel, Lauren V
  • Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Drive, Raleigh, NC, 27607, USA.
Goodale, Margaret B
  • Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA.
Fortier, Lisa A
  • Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA. laf4@cornell.edu.

MeSH Terms

  • Animals
  • Cells, Cultured
  • Chondrocytes / metabolism
  • Cytokines / genetics
  • Cytokines / metabolism
  • Extracellular Matrix Proteins / genetics
  • Extracellular Matrix Proteins / metabolism
  • Female
  • Histocompatibility Antigens Class I / genetics
  • Histocompatibility Antigens Class I / metabolism
  • Histocompatibility Antigens Class II / genetics
  • Histocompatibility Antigens Class II / metabolism
  • Horses
  • Immunomodulation
  • Macrophages / immunology
  • Male
  • Mesenchymal Stem Cells / immunology

Conflict of Interest Statement

ETHICS APPROVAL AND CONSENT TO PARTICIPATE: All procedures for sample collection were approved by the Institutional Animal Care and Use Committee of Cornell University. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

This article includes 48 references
  1. Cassano JM, Schnabel LV, Betancourt AM, Antczak DF, Fortier LA. Mesenchymal stem cell therapy: clinical progress and opportunities for advancement.. Curr Pathobiol Rep 2015;3:1–7.
    doi: 10.1007/s40139-015-0064-4google scholar: lookup
  2. Chen Y, Teng X, Chen W, Yang J, Yang Z, Yu Y, Shen Z. Timing of transplantation of autologous bone marrow derived mesenchymal stem cells for treating myocardial infarction.. Sci China Life Sci 2014 Feb;57(2):195-200.
    doi: 10.1007/s11427-013-4605-ypubmed: 24430558google scholar: lookup
  3. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair.. Nat Rev Rheumatol 2013 Oct;9(10):584-94.
    doi: 10.1038/nrrheum.2013.109pubmed: 23881068google scholar: lookup
  4. Vangsness CT Jr, Farr J 2nd, Boyd J, Dellaero DT, Mills CR, LeRoux-Williams M. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study.. J Bone Joint Surg Am 2014 Jan 15;96(2):90-8.
    doi: 10.2106/JBJS.M.00058pubmed: 24430407google scholar: lookup
  5. De Schauwer C, Van de Walle GR, Van Soom A, Meyer E. Mesenchymal stem cell therapy in horses: useful beyond orthopedic injuries?. Vet Q 2013 Dec;33(4):234-41.
    doi: 10.1080/01652176.2013.800250pubmed: 23697553google scholar: lookup
  6. Sze SK, de Kleijn DP, Lai RC, Khia Way Tan E, Zhao H, Yeo KS, Low TY, Lian Q, Lee CN, Mitchell W, El Oakley RM, Lim SK. Elucidating the secretion proteome of human embryonic stem cell-derived mesenchymal stem cells.. Mol Cell Proteomics 2007 Oct;6(10):1680-9.
    doi: 10.1074/mcp.M600393-MCP200pubmed: 17565974google scholar: lookup
  7. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.. Cell Stem Cell 2012 Mar 2;10(3):244-58.
    doi: 10.1016/j.stem.2012.02.005pmc: PMC3294273pubmed: 22385653google scholar: lookup
  8. Squillaro T, Peluso G, Galderisi U. Clinical Trials With Mesenchymal Stem Cells: An Update.. Cell Transplant 2016;25(5):829-48.
    doi: 10.3727/096368915X689622pubmed: 26423725google scholar: lookup
  9. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis.. Bone Joint Res 2012 Nov;1(11):297-309.
    doi: 10.1302/2046-3758.111.2000132pmc: PMC3626203pubmed: 23610661google scholar: lookup
  10. Smith RK, Werling NJ, Dakin SG, Alam R, Goodship AE, Dudhia J. Beneficial effects of autologous bone marrow-derived mesenchymal stem cells in naturally occurring tendinopathy.. PLoS One 2013;8(9):e75697.
    doi: 10.1371/journal.pone.0075697pmc: PMC3783421pubmed: 24086616google scholar: lookup
  11. Smith RK, Garvican ER, Fortier LA. The current 'state of play' of regenerative medicine in horses: what the horse can tell the human.. Regen Med 2014;9(5):673-85.
    doi: 10.2217/rme.14.42pubmed: 25372081google scholar: lookup
  12. Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R 3rd, Watts AE. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model.. Stem Cell Res Ther 2017 Feb 28;8(1):42.
    doi: 10.1186/s13287-017-0503-8pmc: PMC5329965pubmed: 28241885google scholar: lookup
  13. Szabó E, Fajka-Boja R, Kriston-Pál É, Hornung Á, Makra I, Kudlik G, Uher F, Katona RL, Monostori É, Czibula Á. Licensing by Inflammatory Cytokines Abolishes Heterogeneity of Immunosuppressive Function of Mesenchymal Stem Cell Population.. Stem Cells Dev 2015 Sep 15;24(18):2171-80.
    doi: 10.1089/scd.2014.0581pubmed: 26153898google scholar: lookup
  14. Krampera M. Mesenchymal stromal cell 'licensing': a multistep process.. Leukemia 2011 Sep;25(9):1408-14.
    pubmed: 21617697doi: 10.1038/leu.2011.108google scholar: lookup
  15. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, Genrich K, Mehrotra S, Setty S, Smith B, Bartholomew A. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease.. Eur J Immunol 2008 Jun;38(6):1745-55.
    doi: 10.1002/eji.200738129pmc: PMC3021120pubmed: 18493986google scholar: lookup
  16. Waterman RS, Morgenweck J, Nossaman BD, Scandurro AE, Scandurro SA, Betancourt AM. Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy.. Stem Cells Transl Med 2012 Jul;1(7):557-65.
    doi: 10.5966/sctm.2012-0025pmc: PMC3659725pubmed: 23197860google scholar: lookup
  17. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype.. PLoS One 2010 Apr 26;5(4):e10088.
    doi: 10.1371/journal.pone.0010088pmc: PMC2859930pubmed: 20436665google scholar: lookup
  18. Cui R, Rekasi H, Hepner-Schefczyk M, Fessmann K, Petri RM, Bruderek K, Brandau S, Jäger M, Flohé SB. Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients.. Stem Cell Res Ther 2016 Jul 7;7(1):88.
    doi: 10.1186/s13287-016-0353-9pmc: PMC4937587pubmed: 27388156google scholar: lookup
  19. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling.. J Pathol 2013 Jan;229(2):176-85.
    doi: 10.1002/path.4133pubmed: 23096265google scholar: lookup
  20. Brown BN, Ratner BD, Goodman SB, Amar S, Badylak SF. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine.. Biomaterials 2012 May;33(15):3792-802.
    doi: 10.1016/j.biomaterials.2012.02.034pmc: PMC3727238pubmed: 22386919google scholar: lookup
  21. Ploeger DT, Hosper NA, Schipper M, Koerts JA, de Rond S, Bank RA. Cell plasticity in wound healing: paracrine factors of M1/ M2 polarized macrophages influence the phenotypical state of dermal fibroblasts.. Cell Commun Signal 2013 Apr 19;11(1):29.
    doi: 10.1186/1478-811X-11-29pmc: PMC3698164pubmed: 23601247google scholar: lookup
  22. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
    doi: 10.1186/scrt402pmc: PMC4055004pubmed: 24461709google scholar: lookup
  23. Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices.. Transfusion 2014 May;54(5):1418-37.
    doi: 10.1111/trf.12421pmc: PMC6364749pubmed: 24898458google scholar: lookup
  24. Cavatorta DJ, Erb HN, Felippe MJ. Activation-induced FoxP3 expression regulates cytokine production in conventional T cells stimulated with autologous dendritic cells.. Clin Vaccine Immunol 2012 Oct;19(10):1583-92.
    doi: 10.1128/CVI.00308-12pmc: PMC3485884pubmed: 22855393google scholar: lookup
  25. Fortier LA, Kornatowski MA, Mohammed HO, Jordan MT, O'Cain LC, Stevens WB. Age-related changes in serum insulin-like growth factor-I, insulin-like growth factor-I binding protein-3 and articular cartilage structure in Thoroughbred horses.. Equine Vet J 2005 Jan;37(1):37-42.
    doi: 10.2746/0425164054406838pubmed: 15651732google scholar: lookup
  26. Nixon AJ, Lust G, Vernier-Singer M. Isolation, propagation, and cryopreservation of equine articular chondrocytes.. Am J Vet Res 1992 Dec;53(12):2364-70.
    pubmed: 1476323
  27. Betancourt AM. Mesenchymal stem cells and related therapies.. WO Patent App 2012; PCT/US2011/055831.
  28. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization.. Trends Immunol 2004 Dec;25(12):677-86.
    doi: 10.1016/j.it.2004.09.015pubmed: 15530839google scholar: lookup
  29. Locati M, Mantovani A, Sica A. Macrophage activation and polarization as an adaptive component of innate immunity.. Adv Immunol 2013;120:163-84.
    doi: 10.1016/B978-0-12-417028-5.00006-5pubmed: 24070384google scholar: lookup
  30. Darwich L, Coma G, Peña R, Bellido R, Blanco EJ, Este JA, Borras FE, Clotet B, Ruiz L, Rosell A, Andreo F, Parkhouse RM, Bofill M. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18.. Immunology 2009 Mar;126(3):386-93.
    doi: 10.1111/j.1365-2567.2008.02905.xpmc: PMC2669819pubmed: 18759749google scholar: lookup
  31. Platas J, Guillén MI, del Caz MD, Gomar F, Mirabet V, Alcaraz MJ. Conditioned media from adipose-tissue-derived mesenchymal stem cells downregulate degradative mediators induced by interleukin-1β in osteoarthritic chondrocytes.. Mediators Inflamm 2013;2013:357014.
    doi: 10.1155/2013/357014pmc: PMC3864089pubmed: 24363499google scholar: lookup
  32. Brosnahan MM, Miller DC, Adams M, Antczak DF. IL-22 is expressed by the invasive trophoblast of the equine (Equus caballus) chorionic girdle.. J Immunol 2012 May 1;188(9):4181-7.
    doi: 10.4049/jimmunol.1103509pmc: PMC3746837pubmed: 22490443google scholar: lookup
  33. Tallmadge R. Equine major histocompatibility complex.. Genes Doctoral Thesis 2006.
  34. Remacha AR, Barrachina L, Álvarez-Arguedas S, Ranera B, Romero A, Vázquez FJ, Zaragoza P, Yañez R, Martín-Burriel I, Rodellar C. Expression of genes involved in immune response and in vitro immunosuppressive effect of equine MSCs.. Vet Immunol Immunopathol 2015 Jun 15;165(3-4):107-18.
    doi: 10.1016/j.vetimm.2015.04.004pubmed: 25977164google scholar: lookup
  35. Figueiredo MD, Salter CE, Andrietti AL, Vandenplas ML, Hurley DJ, Moore JN. Validation of a reliable set of primer pairs for measuring gene expression by real-time quantitative RT-PCR in equine leukocytes.. Vet Immunol Immunopathol 2009 Sep 15;131(1-2):65-72.
    doi: 10.1016/j.vetimm.2009.03.013pubmed: 19376596google scholar: lookup
  36. Padoan E, Ferraresso S, Pegolo S, Castagnaro M, Barnini C, Bargelloni L. Real time RT-PCR analysis of inflammatory mediator expression in recurrent airway obstruction-affected horses.. Vet Immunol Immunopathol 2013 Dec 15;156(3-4):190-9.
    doi: 10.1016/j.vetimm.2013.09.020pubmed: 24176614google scholar: lookup
  37. Wimer CL, Damiani A, Osterrieder N, Wagner B. Equine herpesvirus type-1 modulates CCL2, CCL3, CCL5, CXCL9, and CXCL10 chemokine expression.. Vet Immunol Immunopathol 2011 Apr 15;140(3-4):266-74.
    doi: 10.1016/j.vetimm.2011.01.009pubmed: 21349590google scholar: lookup
  38. Taylor SE, Vaughan-Thomas A, Clements DN, Pinchbeck G, Macrory LC, Smith RK, Clegg PD. Gene expression markers of tendon fibroblasts in normal and diseased tissue compared to monolayer and three dimensional culture systems.. BMC Musculoskelet Disord 2009 Feb 26;10:27.
    doi: 10.1186/1471-2474-10-27pmc: PMC2651848pubmed: 19245707google scholar: lookup
  39. Kamm JL, Nixon AJ, Witte TH. Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naturally osteoarthritic equine carpi.. Equine Vet J 2010 Nov;42(8):693-9.
    doi: 10.1111/j.2042-3306.2010.00140.xpmc: PMC4183755pubmed: 21039798google scholar: lookup
  40. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction.. Anal Biochem 1997 Feb 15;245(2):154-60.
    doi: 10.1006/abio.1996.9916pubmed: 9056205google scholar: lookup
  41. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.. Methods 2001 Dec;25(4):402-8.
    doi: 10.1006/meth.2001.1262pubmed: 11846609google scholar: lookup
  42. Mao F, Kang JJ, Cai X, Ding NF, Wu YB, Yan YM, Qian H, Zhang X, Xu WR. Crosstalk between mesenchymal stem cells and macrophages in inflammatory bowel disease and associated colorectal cancer.. Contemp Oncol (Pozn) 2017;21(2):91-97.
    pmc: PMC5611497pubmed: 28947877doi: 10.5114/wo.2017.68616google scholar: lookup
  43. Yu B, Alboslemy T, Safadi F, Kim MH. Glycoprotein Nonmelanoma Clone B Regulates the Crosstalk between Macrophages and Mesenchymal Stem Cells toward Wound Repair.. J Invest Dermatol 2018 Jan;138(1):219-227.
    doi: 10.1016/j.jid.2017.08.034pubmed: 28899684google scholar: lookup
  44. Krstic J, Trivanovic D, Jaukovic A, Santibanez JF, Bugarski D. Metabolic Plasticity of Stem Cells and Macrophages in Cancer.. Front Immunol 2017;8:939.
    doi: 10.3389/fimmu.2017.00939pmc: PMC5552673pubmed: 28848547google scholar: lookup
  45. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Ranera B, Zaragoza P, Martín-Burriel I, Rodellar C. Effect of inflammatory environment on equine bone marrow derived mesenchymal stem cells immunogenicity and immunomodulatory properties.. Vet Immunol Immunopathol 2016 Mar;171:57-65.
    doi: 10.1016/j.vetimm.2016.02.007pubmed: 26964718google scholar: lookup
  46. Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebe L. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.. Cytotherapy 2016 Feb;18(2):151-9.
    doi: 10.1016/j.jcyt.2015.11.008pmc: PMC4745114pubmed: 26724220google scholar: lookup
  47. Waterman RS, Henkle SL, Betancourt AM. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis.. PLoS One 2012;7(9):e45590.
    doi: 10.1371/journal.pone.0045590pmc: PMC3447765pubmed: 23029122google scholar: lookup
  48. Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Res Ther 2015 Apr 12;6(1):54.
    doi: 10.1186/s13287-015-0053-xpmc: PMC4414005pubmed: 25889095google scholar: lookup

Citations

This article has been cited 50 times.
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.